January 29, 2019 / 11:59 AM / 6 months ago

CORRECTED-UPDATE 1-Biogen beats estimates on Spinraza, Tecfidera strength

(Corrects adjusted EPS forecast in paragraph 5 to $28.00-$29.00, from $26.65-$27.65)

Jan 29 (Reuters) - Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, driven by demand for its muscle disease treatment Spinraza and top-selling multiple sclerosis drug Tecfidera.

Spinraza, the first approved treatment for spinal muscular atrophy, brought in $470 million in the quarter, but fell short of analysts' estimate of $487.9 million, according to IBES data from Refinitiv.

Sales of Tecfidera rose 3.2 percent to $1.11 billion, narrowly beating analysts' estimates of $1.10 billion.

Net income attributable to Biogen was $946.8 million, or $4.73 per share, for the three months ended Dec. 31, compared with a net loss of $297.4 million, or $1.40 per share, a year earlier, which included a charge of $1.2 billion related to the U.S. tax overhaul.

The company expects full-year adjusted earnings in the range of $28.00 to $29.00 per share. Analysts were expecting $27.94.

Excluding items, it earned $6.99 per share, above the average analyst estimate of $6.73.

Total revenue here rose 6.6 percent to $3.53 billion, exceeding estimate of $3.40 billion. (Reporting by Manogna Maddipatla and Saumya Sibi Joseph in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below